Prognostic Model of Elderly Hodgkin Lymphoma in China

January 20, 2026 updated by: Huilai Zhang, Tianjin Medical University Cancer Institute and Hospital

Clinical Characteristics and Prognostic Model Analysis of Elderly Patients With Hodgkin Lymphoma in China

This multicenter observational cohort study is based on a patient registry designed to systematically collect uniform real-world clinical data from elderly patients with Hodgkin lymphoma (HL) in China. The registry captures demographic characteristics, disease features, laboratory parameters, treatment patterns, and longitudinal survival outcomes to support predefined scientific objectives.

The primary analysis uses retrospectively collected registry data, with prospectively accrued data incorporated for external validation of a prognostic prediction model. This registry-based study aims to improve risk stratification and inform individualized clinical decision-making for elderly patients with HL in routine clinical practice.

Study Overview

Status

Active, not recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300060
        • Tianjin Cancer Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population consists of elderly patients aged 60 years or older with histologically confirmed Hodgkin lymphoma. Eligible patients include those diagnosed with classical Hodgkin lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma who were treatment-naïve at initial diagnosis.

All patients have complete clinical, pathological, and follow-up data available. Patients with other concurrent malignant tumors, severe hepatic or renal dysfunction, or missing more than 20% of required clinical data are excluded from the study.

Description

Inclusion Criteria:

  • Age ≥60 years
  • Histologically confirmed Hodgkin lymphoma, including classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma
  • Treatment-naïve patients who have not received prior anti-Hodgkin lymphoma therapy
  • Availability of complete clinical, pathological, and follow-up data

Exclusion Criteria:

  • Presence of other malignant tumors
  • Severe hepatic or renal dysfunction (Child-Pugh class C or estimated glomerular filtration rate <30 mL/min)
  • Missing more than 20% of required clinical data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Elderly patients with Hodgkin lymphoma
Observational Cohort

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Survival (OS)
Time Frame: From date of diagnosis until death from any cause, assessed up to 60 months.
Overall survival (OS) is defined as the time from diagnosis to death from any cause.
From date of diagnosis until death from any cause, assessed up to 60 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Progression-Free Survival (PFS)
Time Frame: From date of diagnosis until the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 60 months.
Progression-free survival (PFS) is defined as the time from diagnosis to disease progression or death from any cause.
From date of diagnosis until the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 60 months.
Disease-Free Survival (DFS)
Time Frame: From date of first documented remission until disease relapse or death from any cause, whichever occurs first, assessed up to 60 months.
Disease-free survival (DFS) is defined as the time from remission to disease relapse or death from any cause.
From date of first documented remission until disease relapse or death from any cause, whichever occurs first, assessed up to 60 months.
Event-Free Survival (EFS)
Time Frame: From date of diagnosis until treatment failure, disease relapse, or death from any cause, whichever occurs first, assessed up to 60 months.
Event-free survival (EFS) is defined as the time from diagnosis to treatment failure, disease relapse, or death from any cause.
From date of diagnosis until treatment failure, disease relapse, or death from any cause, whichever occurs first, assessed up to 60 months.
Proportion of Participants With Disease Progression or Death Within 24 Months From Diagnosis (POD24)
Time Frame: From date of diagnosis to 24 months after diagnosis.
Progression of disease within 24 months (POD24) is defined as the occurrence of documented disease progression or death from any cause within 24 months from the date of diagnosis.
From date of diagnosis to 24 months after diagnosis.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 9, 2025

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2028

Study Registration Dates

First Submitted

December 16, 2025

First Submitted That Met QC Criteria

January 20, 2026

First Posted (Actual)

January 28, 2026

Study Record Updates

Last Update Posted (Actual)

January 28, 2026

Last Update Submitted That Met QC Criteria

January 20, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TCH-HL-ELDER-2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hodgkin Lymphoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe